Akums Drugs IPO
GMP, Subscription, Price, Dates & Financial Details
Akums Drugs and Pharmaceuticals Limited, established in 2004, is a leading pharmaceutical contract development and manufacturing organization (CDMO) providing a comprehensive range of products and services in India and internationally. The company offers end-to-end solutions for product…
Open Date
Tue, 30 Jul 2024
Close Date
Thu, 01 Aug 2024
Price Band
₹ 646 – 679
Lot Size
22
Issue Size
₹ 1,856.74 Cr
Minimum Investment
₹ 14,938 (22 Shares)
Grey Market Premium Analysis
Day Wise GMP→Unofficial premium quoted in the grey market, tracked daily against the price band cap.
Grey market trading is unregulated. GMP figures are indicative only and should not be the sole basis for investment decisions - treat as a sentiment indicator, not a guarantee.
IPO Details
Akums Drugs IPO has successfully completed its IPO process and is now listed on the NSE and BSE. According to the Red Herring Prospectus (RHP), the IPO was a book-built issue with a total issue size of ₹1,857 Crore, comprising a fresh issue of 1.00 Crore equity shares aggregating to ₹680.00 Crore and an offer for sale (OFS) of 1.73 Crore equity shares aggregating to ₹1,176.74 Crore by the existing shareholders.
The Akums Drugs IPO remained open for subscription from July 30, 2024, to August 01, 2024. The basis of allotment was finalized on August 02, 2024, and the company's shares were listed on the NSE and BSE on August 06, 2024.
The company had fixed the price band at ₹646 to ₹679 per share, with a lot size of 22 shares. Retail investors were required to make a minimum investment of ₹14,938 (based on the upper price band) to apply for one lot.
The IPO also included a reservation of 243,902 equity shares for eligible employees, who received a discount of ₹64 per share.
MUFG Intime India Private Limited served as the registrar to the issue. Axis Bank Limited, Citigroup Global Markets India Private Limited, Ambit Private Limited, and ICICI Securities Limited acted as the Book Running Lead Managers (BRLMs) to the issue.
With the successful completion of the IPO process, Akums Drugs and Pharmaceuticals Limited is now a publicly listed company on the NSE and BSE. Investors can track the company's share price, trading performance, financial results, and corporate announcements through the stock exchanges.
Akums Drugs IPO Timeline (Tentative)
- IPO Open Date
- Tue, 30 Jul 24
- IPO Close Date
- Thu, 01 Aug 24
- Basis of Allotment
- Fri, 02 Aug 24
- Initiation of Refunds
- Mon, 05 Aug 24
- Credit of Shares to Demat
- Mon, 05 Aug 24
- Listing Date
- Tue, 06 Aug 24 — NSE & BSE
Open Date
30 July 2024
Close Date
01 August 2024
Basis Of Allotment
02 August 2024
Listing Date
06 August 2024
IPO Subscription
Check Live Subscription →The Akums Drugs IPO has received bids for 96,36,79,134 shares against 1,51,62,239 shares offered, resulting in an overall subscription of 63.56x. the NII category is subscribed 42.21x, Retail Investors 21.3x, Employees 4.27x, and QIBs 90.09x. Within the NII category, BNII is subscribed 47.43x, while SNII is subscribed 31.78x.
QIB
90.09x
NII
42.21x
BNII
47.43x
SNII
31.78x
RII
21.3x
EMP
4.27x
Total
63.56x
IPO Reservations
The Retail Individual Investor (RII) category has the highest allocation with 27,12,424 shares, representing 9.91% of the total issue. Qualified Institutional Buyers (QIBs) are allocated 81,37,276 shares (29.73%), while Non-Institutional Investors (NIIs) receive 40,68,637 shares (14.87%).
| Category | Shares Offered | Shares Offered |
|---|---|---|
| Anchor Investors | 12,205,912 | 44.6% |
| Qualified Institutions | 8,137,276 | 29.73% |
| Non-Institutional | 4,068,637 | 14.87% |
| BNII | 2,712,425 | 9.91% |
| SNII | 1,356,212 | 4.96% |
| Retail Investors | 2,712,424 | 9.91% |
| Employees | 243,902 | 0.89% |
| Total | 27,368,151 | 100% |
Financials Details(₹ in Crores)
| Particular | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Assets | 3516.37 | 3266.53 | 3069.05 |
| Revenue | 4212.21 | 3700.93 | 3694.52 |
| Profit After Tax | 0.79 | 97.82 | -250.87 |
| Net Worth | 709.5 | 717.19 | 621.98 |
| Reserve & Surplus | 861.01 | 868.7 | 787.79 |
| Total Borrowings | 491.56 | 536.97 | 357.95 |
Financials Performance
Performance Indicators
EPS Pre
Earnings per share before the IPO.
P/E Pre
IPO Offer Price ÷ EPS Pre.
EPS Post
Expected earnings per share after the IPO..
P/E (Post Issue)
IPO Offer Price ÷ EPS Post.
Akums Drugs and Pharmaceuticals Limited KPI Information
| Particular | KPI as of March 31, 2024. |
|---|---|
| ROE % | 0.11 |
| ROCE % | 3.37 |
| Debt / Equity | 0.69 |
| RoNW % | -0.57 |
| PbW | 13.69 |
| Pat Margin % | 0.02 |
Peers Comparison
No Peer Comparision Available
About Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited, established in 2004, is a leading pharmaceutical contract development and manufacturing organization (CDMO) providing a comprehensive range of products and services in India and internationally.
The company offers end-to-end solutions for product development, manufacturing, research and development (R&D) of formulations, regulatory dossier preparation, and submission, along with other testing services. Akums is also involved in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).
As a CDMO, Akums produces a variety of dosage forms, including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections, and gummy bears. The company has commercialised 4,025 formulations in over 60 dosage forms and, in 2023, manufactured formulations for 26 of India's top 30 pharmaceutical companies by revenue. Akums operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually as of September 30, 2023.
Akums Drugs IPO Promoters
- Sanjeev Jain
- Sandeep Jain
- Akums Master Trust
Promoters Holding
Holding Pre Issue
84.94%
Holding Post Issue
0.00%
Akums Drugs IPO Objective
The Company proposes to utilize the Net Proceeds towards the funding of the following objects:
- Repayment/ prepayment of indebtedness of the company and its Subsidiaries
- Funding incremental working capital requirements of the company
- Pursuing inorganic growth initiatives through acquisitions
- General corporate purposes.
Akums Drugs and Pharmaceuticals Limited Address / Contact Details
Akums Drugs and Pharmaceuticals Limited
304, Mohan Place,
LSC Saraswati Vihar,
Delhi - 110 034
Phone: +91 11 6904 1000
Email: cs@akums.net
Website: http://www.akums.in
IPO Snapshot
Akums Drugs IPO Lot Size
The Akums Drugs IPO has a lot size of 22 shares. Retail investors require a minimum investment of ₹14,938 by applying for 1 lot (22 shares). The maximum application allowed for the retail category is 13 lots (286 shares), requiring an investment of ₹1,94,194.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 22 | 14,938.00 |
| Retail (Max) | 13 | 286 | 194,194.00 |
| S-HNI (Min) | 14 | 308 | 209,132.00 |
| S-HNI (Max) | 66 | 1,452 | 985,908.00 |
| B-HNI (Min) | 67 | 1,474 | 1,000,846.00 |
Issue Reservation
- Anchor Investors — 44.6%
- QIB — 29.73%
- NII — 14.87%
- RII — 9.91%
- EMP — 0.89%
Book Running Lead Managers
- Axis Bank Limited
- Citigroup Global Markets India Private Limited
- Ambit Private Limited
- ICICI Securities Limited
IPO Documents & Links
Explore More IPOs
Currently Open
Coming Up Next
Disclaimer: This data is for informational purposes only and does not constitute investment advice.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Akums Drugs IPO?
Akums Drugs IPO is a Book-building IPO with a total issue size of ₹1856.74 crore. The Akums Drugs IPO price band is ₹646 to 679 per share. The Akums Drugs IPO subscription opens on Tue, Jul 30, 2024, and closes on Thu, Aug 1, 2024. The Akums Drugs IPO will be listed on the NSE,BSE. MUFG Intime India Private Limited is the registrar for the Akums Drugs IPO.
When will the Akums Drugs IPO open for subscription?
The Akums Drugs IPO opens on Tue, Jul 30, 2024 and closes on Thu, Aug 1, 2024
What is Akums Drugs IPO Price Band?
Akums Drugs IPO Price Band is ₹646 to 679 per share.
What is Akums Drugs IPO Lot Size?
Akums Drugs IPO lot size is 22 shares, Retail investors need a minimum investment of ₹14938 based on the upper price band
What is the minimum investment for Akums Drugs IPO?
The minimum investment for Akums Drugs IPO is ₹14938, based on one lot of 22 shares at the upper price band of ₹679 per share.
How to apply for Akums Drugs IPO?
Investors can apply for the Akums Drugs IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Thu, Aug 1, 2024. The application amount remains blocked until the Akums Drugs IPO allotment is finalized.
What is Akums Drugs IPO Issue Size?
Akums Drugs IPO issue size is ₹1856.74 crores.
What is the Akums Drugs IPO Allotment Date?
Akums Drugs IPO allotment date is Fri, Aug 2, 2024.
Who is the Akums Drugs IPO Registrar?
The registrar for Akums Drugs IPO is MUFG Intime India Private Limited. Investors can go to MUFG Intime India Private Limited website to check Akums Drugs IPO allotment status, refund processing, and other IPO-related information.
What is the Akums Drugs IPO GMP?
The Akums Drugs IPO GMP (Grey Market Premium) is ₹43 as of Tue, Aug 6, 2024. Based on the upper price band of ₹679 per share, the estimated Akums Drugs IPO listing price is ₹722, indicating a potential listing gain of approximately 6.33% over the issue price.
Who is the Akums Drugs IPO Lead Manager?
The book-running lead managers (BRLMs) for the Akums Drugs IPO are Citigroup Global Markets India Private Limited, Ambit Private Limited, and ICICI Securities Limited. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Akums Drugs IPO Red Herring Prospectus (RHP).